Supplementary Tables 1-3 from A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer

Supplementary Table S1. Pharmacokinetic parameters for enzalutamide administered as a single oral dose administered on day 1 to women with breast cancer and and on day 49 to men with prostate cancer; Supplementary Table S2. Pharmacokinetic parameters for enzalutamide and its active metabolite in patients taking enzalutamide 160 mg once daily to steady state; Supplementary Table S3. Most common grade ≥3 adverse events in more than one patient in the safety population.